BHVN

Biohaven Ltd.

NYSE: BHVN · HEALTHCARE · BIOTECHNOLOGY

$15.52

+1.50% today

Updated 2026-10-28

Market cap

$1.63B

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-4.56

Dividend yield

—

52W range

$7 – $19

Volume

3.5M

Market cap

$1.63B

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-4.56

Dividend yield

—

52W range

$7 – $19

Volume

3.5M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

4.0

Quality

3.0

Profitability

5.0

Valuation

C+

1/9

Piotroski F-Score

Weak

-11.1

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →270 stocks currently score above 75

Price targets

Analyst target

$21.27

+37.05%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

3 Strong Buy9 Buy4 Hold0 Sell1 Strong Sell

Price chart

Stock snapshot

Strengths

Insufficient data

Risks

- Piotroski 1/9 — weak financial health

- Altman Z -11.11 — distress zone

- Thin margins at 0.00%

- Negative free cash flow $-85.55M

- Debt/equity 24.30x — high leverage

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Net income	$-570.28M	$-408.17M	$-846.42M	$-738.82M	$-137.31M
EPS	—	—	—	—	$-4.56
Free cash flow	$-338.76M	$-334.77M	$-586.50M	$-610.15M	$-85.55M
Profit margin	—	—	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
BHVN	$1.63B	23	4.3	3.0	5.0	4.0	—	Avoid
LLY	$1.12T	76	9.3	10.0	5.0	6.0	—	Strong Buy
JNJ	$615.87B	57	4.7	8.5	2.7	5.5	-83.05%	Buy
ABBV	$504.37B	73	6.7	8.5	4.0	5.0	-86.73%	Strong Buy
UNH	$360.32B	62	6.7	6.0	4.7	5.5	-25.92%	Buy
MRK	$360.08B	36	4.0	4.5	2.0	5.0	-73.68%	Hold

Smart narrative

Biohaven Ltd. trades at $15.52. Our Smart Value Score of 23/100 indicates the stock is weak. The company scores 1/9 on the Piotroski F-Score. With an Altman Z-Score of -11.11, it sits in the distress.

Frequently asked questions

What is Biohaven Ltd.'s stock price?

Biohaven Ltd. (BHVN) trades at $15.52.

Is Biohaven Ltd. overvalued?

Biohaven Ltd. carries a Smart Value Score of 23/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.

What is the price target of Biohaven Ltd. (BHVN)?

The 12-month analyst consensus target is $21.27, about 37.0% above the current $15.52. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.

Altman Z-Score?

Biohaven Ltd.'s Altman Z-Score is -11.11, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNYSE

CurrencyUSD

Quick metrics

P/S ratio—

ROE-500.14%

Beta3.20

50D MA$13.68

200D MA$12.07

Shares out0.15B

Float0.12B

Short ratio—

Avg volume3.5M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

BHVN vs LLY →BHVN vs JNJ →BHVN vs ABBV →Stock screener →